cms.bioaccessla.com

Tag: Clinical trial startup

  • Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil continues to be one of the most important anchors for early-stage clinical development in Latin America, but the compliance baseline is moving. In 2026, Anvisa highlighted that Brazil’s clinical research environment has been updated through Law No. 14.874/2024 (ethical aspects of research with human beings) and the newer regulatory package RDC 945/2024 plus IN 338/2024 for clinical research supporting registration of medicines, which Anvisa notes took effect in early 2025 (Anvisa).

    For MedTech founders and regulatory directors planning first-in-human (FIH) or early pivotal work in the region, the strategic opportunity remains: access to experienced investigators, high-quality sites, and diverse patient populations. The operational requirement, however, is to design submissions, vendor oversight, and essential documentation so you can demonstrate control at any moment—especially as inspection programs mature.

    1) What changed in Brazil’s research governance—and why it matters for sponsors

    Anvisa’s 2025 activity reporting explicitly connects the new ethical law and the updated clinical research regulation to the agency’s current oversight approach (Anvisa). In parallel, Anvisa’s inspection metrics reporting emphasizes inspection readiness against GCP expectations (ICH E6 (R2) or updates) while referencing RDC 945/2024 and Law 14.874/2024 as part of the inspection framework (Anvisa).

    Practical takeaway: even when timelines are competitive, sponsors should assume that documentation quality, vendor governance, and data integrity controls will be evaluated more explicitly. This is good news for well-prepared early-stage teams: strong fundamentals can shorten back-and-forth with sites and reduce downstream remediation.

    2) A sponsor-ready timeline: how to think about “FIH speed” without compliance debt

    Internal execution experience across Latin American programs repeatedly shows that speed usually breaks down in predictable places: incomplete essential documents, misaligned responsibilities between sponsor and CRO, and late-stage changes to protocol and informed consent artifacts. Treat “speed” as a systems outcome rather than a hero effort.

    • Pre-submission (4–8 weeks): lock protocol operational feasibility, confirm investigational product/device logistics, and establish a document control plan.
    • Submission-ready package: create a single source of truth for protocol, IB/IFU (as applicable), safety reporting plan, and data handling plan.
    • Site activation: standardize training, delegation, and vendor onboarding so the first site is not a one-off build.

    Many startups underestimate that “time to first patient” is often constrained by operational readiness, not just authority review. Investing early in a repeatable activation model is one of the highest ROI moves you can make.

    3) Inspection readiness: build once, benefit for years

    Anvisa’s inspection metrics report notes its focus on inspections conducted in 2024 and 2025 and positions inspections as a tool to protect participants and data integrity (Anvisa). For early-stage sponsors, the implication is clear: build inspection readiness into your operating rhythm rather than treating it as a “phase 3 problem.”

    Start with five non-negotiables:

    • Essential document discipline: version control, signatures, and clear ownership.
    • Delegation and training: role-based training mapped to tasks; keep it auditable.
    • Deviation and CAPA workflow: define severity levels and timelines; trend issues.
    • Vendor oversight: documented qualification, KPIs, and periodic review for CROs, labs, and logistics partners.
    • Data integrity: audit trails, access controls, and reconciliation between source, eCRF, and safety database.

    4) How to operationalize this across Latin America (not just Brazil)

    Brazil is rarely the only country in a Latin America strategy. Use Brazil as the quality anchor and replicate the same operating system across additional countries. You can localize what must be localized (ethics committee formats, language, import processes), while keeping your core compliance artifacts stable.

    A useful mental model: create a regional master file (core documents, SOPs, training), plus country modules (local submissions, contracts, import permits), plus site modules (delegation, logs, training, monitoring).

    FAQ

    When did Brazil’s latest clinical research regulations take effect?
    Brazil’s updated framework referenced by Anvisa includes Law 14.874/2024 (in force since 29 Aug 2024) and RDC 945/2024 plus IN 338/2024 (effective 2 Jan 2025).

    Do these changes apply to medical devices too?
    The Anvisa updates cited relate to clinical research for registration of medicines and biologics; device sponsors should still align operational quality systems and inspection readiness to ICH GCP expectations and local ethics requirements.

    How should startups prepare for inspection readiness?
    Build inspection-ready documentation from day one: role-based training, version-controlled essential documents, delegation logs, deviation management, and vendor oversight that can be demonstrated quickly.

    Need help designing a Latin America FIH plan? bioaccess® supports sponsors with regional feasibility, activation, and execution strategies built for speed and inspection readiness.

  • Brazil’s 90‑Business‑Day ANVISA Clock: A First‑in‑Human Activation Timeline for MedTech

    Brazil’s 90‑Business‑Day ANVISA Clock: A First‑in‑Human Activation Timeline for MedTech

    For MedTech founders and regulatory directors, “first patient in” is not a single milestone—it is the outcome of dozens of parallel workstreams that must converge at the right time. Brazil has become an increasingly attractive environment for early-stage studies because the country’s regulatory pathway has defined review timelines for parts of the process, including a 90-business-day window for ANVISA’s analysis of key clinical trial petitions as described by the U.S. NIH’s ClinRegs Brazil overview.

    But a fast clock on paper does not automatically translate into a fast activation in practice. Sponsors still lose weeks when ethics submissions, ANVISA dossiers, import readiness, and site enablement are treated as sequential tasks rather than an integrated program. This article provides a practical first-in-human (FIH) activation timeline for Brazil—designed for medical devices and combination products—so teams can predict the critical path, reduce avoidable rework, and protect study quality.

    Why Brazil is different for early-stage activation

    Brazil’s clinical research oversight operates as a dual system. On the regulatory side, ANVISA is responsible for clinical trial oversight, approvals, and inspections. On the ethics side, institutional Research Ethics Committees (CEPs) and the National Research Ethics Commission (CONEP) safeguard participant rights and may be required for certain studies, including some with foreign sponsorship. ClinRegs notes that clinical trials may only begin after both ethics and ANVISA approvals are in place, and that sponsors can submit in parallel rather than waiting for one decision before starting the other.

    For FIH programs, the key operational insight is that “parallel” only works if your team pre-builds the dossier and operational backbone in a way that prevents late-stage gaps. That means aligning protocol, investigator’s brochure (or device equivalent), risk management, investigational product logistics, and site readiness into one activation plan.

    A practical FIH activation timeline (week-by-week)

    The timeline below is a planning template. Your specific path will vary based on device risk class, whether the product is a device-only investigation or a drug-device combination, whether import is required, and whether CONEP review applies. Still, most FIH teams benefit from managing the activation plan as six overlapping phases.

    Phase 1 (Weeks 0–2): Activation blueprint and dossier alignment

    • Define the activation goal: first patient in, first-in-country, or first site activated—then translate it into a dated plan with owners.
    • Freeze core scientific documents: protocol, statistical approach (if applicable), investigator brochure/device technical file summary, informed consent draft, and safety monitoring plan.
    • Pre-brief sites: confirm investigator interest, feasibility, patient pool, and required imaging/lab capabilities.
    • Map the import path: determine whether investigational product import will be needed, what documents are required, and when to initiate customs planning.

    Common pitfall: teams treat feasibility as “business development,” then discover late that the site cannot execute key assessments. For FIH studies, feasibility should be treated as a protocol risk-control activity.

    Phase 2 (Weeks 2–4): Parallel submission readiness (ethics + ANVISA)

    ClinRegs indicates that clinical trial applications can be submitted in parallel in Brazil. Use that advantage. Your objective in this phase is not merely to “submit,” but to submit dossiers that survive the first pass without avoidable queries.

    • Ethics package readiness: ensure Portuguese-language materials, recruitment approach, participant protections, investigator CVs, and site documentation are complete.
    • Regulatory package readiness: align device description, risk analysis, prior testing, clinical rationale, and monitoring approach into an internally consistent narrative.
    • Operational readiness: contract templates, budget assumptions, data capture approach, and vendor onboarding plan.

    Tip: run an internal “approval simulation” meeting before submission. Ask: if the reviewer questions the risk–benefit logic, do we have a clear answer embedded in the dossier?

    Phase 3 (Weeks 4–10): Review window management and rapid-response loop

    ClinRegs describes a 90-business-day timeframe for ANVISA’s analysis of key clinical trial dossiers, with defined sponsor response windows when additional information is requested. Even with set timelines, the sponsor’s responsiveness and document discipline often determine whether the review stays on track.

    • Stand up a “question-response” war room: pre-assign technical owners (clinical, quality, regulatory, biostatistics, logistics) so questions can be addressed within days, not weeks.
    • Maintain a single source of truth: track every submitted document version and every response in a controlled repository.
    • Keep sites warm: train coordinators, initiate essential vendor qualification, and prepare for SIV scheduling so you can start immediately after approvals.

    Common pitfall: teams wait for approval before planning site initiation, then lose 2–4 weeks to avoidable scheduling and vendor delays.

    Phase 4 (Weeks 8–12): Import and investigational product readiness

    FIH programs fail more often from logistics than from science. If you need to import devices, kits, or ancillary supplies, design the import process as a parallel track, not an afterthought.

    • Confirm labeling and packaging requirements: ensure your investigational labeling supports clinical-use workflows and aligns with the protocol.
    • Build a customs-ready document pack: commercial invoice equivalents, certificates, and product descriptions that minimize ambiguity.
    • Create a buffer strategy: hold contingency inventory or stage supplies locally when feasible.

    Tip: for FIH devices, plan at least one “mock shipment” exercise or logistics rehearsal, even if it’s document-only. The point is to find gaps while time remains.

    Phase 5 (Weeks 10–14): Site initiation and first patient in

    • Run targeted SIVs: prioritize protocol-critical procedures, safety reporting, and data integrity steps.
    • Operationalize screening: define screening triggers, referral pathways, and investigator decision trees.
    • Monitor early execution: the first 1–3 patients usually reveal whether your trial design is workable in the real world.

    Common pitfall: launching without clear screening criteria and without real-time visibility into early deviations. For FIH, early deviations often signal that the trial design needs operational adjustments.

    Phase 6 (Weeks 14+): Stabilize, scale sites, and protect data quality

    • Scale site network deliberately: expand only after the first site demonstrates protocol adherence and predictable enrollment.
    • Harden the safety loop: ensure rapid reporting, investigator training, and sponsor review cadence.
    • Maintain audit readiness: document control and deviation management are not optional; they are how you preserve the value of your data for future submissions.

    Checklist: What to pre-build before you submit

    • Protocol + operational workflow map (how each visit is executed at the site)
    • Device/technology summary that is consistent across regulatory, ethics, and site materials
    • Risk management narrative that ties hazards to mitigations and monitoring
    • Import-readiness pack with clear product descriptors and shipping plan
    • Vendor onboarding plan (labs, imaging, data capture, logistics) aligned to activation dates
    • Response war room with named owners and draft response templates

    FAQ

    1) Can we submit to ethics and ANVISA at the same time in Brazil?

    Yes. ClinRegs indicates that clinical trial applications can be submitted in parallel, but trials should not start until both approvals are in place. The operational value is in reducing idle time by building parallel readiness workstreams.

    2) What typically delays first-in-human activation the most?

    In many FIH programs, delays come from late dossier inconsistencies, slow responses to reviewer questions, and underestimated import and site-startup tasks. Treat activation as a program with a critical path rather than a compliance checklist.

    3) How do we protect data quality while moving fast?

    Move fast by reducing rework—not by cutting corners. Standardize document control, train sites on protocol-critical steps, and implement real-time deviation monitoring so you can correct execution issues early.

    Educational content only. Sponsors should consult qualified regulatory and clinical research professionals for study-specific planning.

  • Brazil’s 90 Day Clinical Trial Clock: A Practical Activation Playbook For First-In-Human Studies

    Brazil’s 90-Day Clinical Trial Clock: A Practical Activation Playbook for First-in-Human Studies

    For MedTech founders and regulatory leaders, Brazil has quietly become one of the most “plannable” countries in Latin America for early-stage clinical activation. A core reason is Brazil’s recent legal and regulatory modernization, which introduced a defined review window and clearer guardrails for starting studies.

    This article translates the change into a sponsor-facing activation playbook: what the 90-business-day clock means, how it interacts with ethics approvals, and what you should build into your timeline to avoid rework. The goal is not to “rush” a trial—it’s to make your activation schedule predictable and audit-ready.

    1) What changed in Brazil (and why it matters for FIH planning)

    Brazil’s Law No. 14.874/2024 established a national system of ethics in research involving humans and introduced a defined 90-business-day review window for ANVISA’s assessment of clinical trial applications that support marketing authorization.

    In practical terms, this is a planning upgrade. Sponsors can build a realistic activation calendar, align manufacturing and logistics windows, and avoid “open-ended” waiting periods that often inflate costs in early-stage programs.

    Importantly, Brazil still requires both ethics approval and ANVISA approval before initiation. However, the rules allow parallel submission so you can run key workstreams concurrently rather than serially.

    2) The activation sequence: ethics, ANVISA, and parallelization

    For most sponsors, the fastest compliant path is a two-track plan:

    • Track A (Ethics): prepare site documents, informed consent, investigator materials, and submit to the local ethics committee process.
    • Track B (Regulatory): prepare the ANVISA dossier and submit in parallel, ensuring your package is consistent with what ethics committees will see.

    A common pitfall is treating ethics and regulatory packages as separate artifacts. Instead, use a single “source of truth” for protocol versioning, risk language, endpoints, and safety reporting workflows.

    3) Don’t miss the hidden gating item: the trial-specific dossier

    Brazil’s process includes a key practical requirement: ANVISA’s technical analysis of the primary petition may depend on the filing of a trial-specific dossier. That means your internal readiness must include not only the umbrella development dossier, but also at least one trial-specific submission with the minimum documentation set.

    Operational takeaway: build your activation plan around “dossier completeness” milestones, not just “submission sent.” Sponsors who plan only to the submission date often discover late-stage gaps in translations, investigational product documentation, or safety reporting alignment.

    4) What “decurso de prazo” means (and what it does NOT mean)

    Brazil’s reforms also created an important concept often summarized as decurso de prazo: if the health authority does not issue a decision within the legal timeline and the study has the required ethics approvals, clinical development can begin.

    For sponsors, this is best treated as a risk-managed backstop rather than a default strategy. Your activation plan should still assume you will operate with an explicit authorization outcome and complete documentation. Use the statutory timeline to reduce uncertainty—not to reduce diligence.

    5) A sponsor-ready 90-day activation checklist

    If you want to benefit from predictable timelines, your internal systems must be “startup-ready” before the clock runs out. Here is a checklist that consistently prevents avoidable delays:

    • Regulatory narrative consistency: protocol synopsis, device/drug description, intended use, and risk statements match across all documents.
    • Import and labeling readiness: confirm investigational supply chain steps, packaging needs, and local labeling conventions early.
    • Safety workflow: clear SAE reporting path, vendor responsibilities, and escalation coverage (including weekends/holidays).
    • Data integrity: eCRF, source templates, and monitoring plan support inspection readiness from Day 1.
    • Site enablement: training plan, delegation logs, and equipment calibration records are not afterthoughts.

    6) How to use Brazil strategically inside a Latin America multi-country plan

    Many early-stage sponsors run a multi-country Latin America strategy to balance speed, cost, and enrollment diversity. Brazil’s clearer timeline can play multiple roles:

    • Anchor country: you plan your “first patient in” forecast around a predictable activation window.
    • Evidence builder: you generate high-quality data to support later reimbursement or regulatory submissions elsewhere.
    • Operational benchmark: you standardize SOPs and monitoring routines that can be replicated across the region.

    The key is harmonization: standardize your core protocol and quality system while adapting country-level workflows (ethics requirements, import pathways, and contracting norms).

    FAQ

    Does Brazil still require ethics approval before starting a clinical trial?

    Yes. Sponsors should plan for both ethics and regulatory authorization and use parallel workstreams to compress time without compromising compliance.

    Is the 90-business-day period a guarantee that my trial will be approved?

    No. It is a defined review window that improves predictability; approval still depends on dossier completeness and meeting regulatory and ethical requirements.

    What is the biggest activation mistake sponsors make in Brazil?

    Underestimating the time to assemble a trial-specific dossier and align all documents (protocol, consent, IP description, safety reporting). “Submitted” does not equal “complete.”

    Bottom line: Brazil’s reform is a planning advantage. Sponsors who pair it with disciplined document control, parallel submission strategy, and site readiness can reduce activation uncertainty—one of the most expensive problems in early-stage trials.

  • Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil continues to be one of the most important anchors for early-stage clinical development in Latin America, but the compliance baseline is moving. In 2026, Anvisa highlighted that Brazil’s clinical research environment has been updated through Law No. 14.874/2024 (ethical aspects of research with human beings) and the newer regulatory package RDC 945/2024 plus IN 338/2024 for clinical research supporting registration of medicines, which Anvisa notes took effect in early 2025 (Anvisa).

    For MedTech founders and regulatory directors planning first-in-human (FIH) or early pivotal work in the region, the strategic opportunity remains: access to experienced investigators, high-quality sites, and diverse patient populations. The operational requirement, however, is to design submissions, vendor oversight, and essential documentation so you can demonstrate control at any moment—especially as inspection programs mature.

    1) What changed in Brazil’s research governance—and why it matters for sponsors

    Anvisa’s 2025 activity reporting explicitly connects the new ethical law and the updated clinical research regulation to the agency’s current oversight approach (Anvisa). In parallel, Anvisa’s inspection metrics reporting emphasizes inspection readiness against GCP expectations (ICH E6 (R2) or updates) while referencing RDC 945/2024 and Law 14.874/2024 as part of the inspection framework (Anvisa).

    Practical takeaway: even when timelines are competitive, sponsors should assume that documentation quality, vendor governance, and data integrity controls will be evaluated more explicitly. This is good news for well-prepared early-stage teams: strong fundamentals can shorten back-and-forth with sites and reduce downstream remediation.

    2) A sponsor-ready timeline: how to think about “FIH speed” without compliance debt

    Internal execution experience across Latin American programs repeatedly shows that speed usually breaks down in predictable places: incomplete essential documents, misaligned responsibilities between sponsor and CRO, and late-stage changes to protocol and informed consent artifacts. Treat “speed” as a systems outcome rather than a hero effort.

    • Pre-submission (4–8 weeks): lock protocol operational feasibility, confirm investigational product/device logistics, and establish a document control plan.
    • Submission-ready package: create a single source of truth for protocol, IB/IFU (as applicable), safety reporting plan, and data handling plan.
    • Site activation: standardize training, delegation, and vendor onboarding so the first site is not a one-off build.

    Many startups underestimate that “time to first patient” is often constrained by operational readiness, not just authority review. Investing early in a repeatable activation model is one of the highest ROI moves you can make.

    3) Inspection readiness: build once, benefit for years

    Anvisa’s inspection metrics report notes its focus on inspections conducted in 2024 and 2025 and positions inspections as a tool to protect participants and data integrity (Anvisa). For early-stage sponsors, the implication is clear: build inspection readiness into your operating rhythm rather than treating it as a “phase 3 problem.”

    Start with five non-negotiables:

    • Essential document discipline: version control, signatures, and clear ownership.
    • Delegation and training: role-based training mapped to tasks; keep it auditable.
    • Deviation and CAPA workflow: define severity levels and timelines; trend issues.
    • Vendor oversight: documented qualification, KPIs, and periodic review for CROs, labs, and logistics partners.
    • Data integrity: audit trails, access controls, and reconciliation between source, eCRF, and safety database.

    4) How to operationalize this across Latin America (not just Brazil)

    Brazil is rarely the only country in a Latin America strategy. Use Brazil as the quality anchor and replicate the same operating system across additional countries. You can localize what must be localized (ethics committee formats, language, import processes), while keeping your core compliance artifacts stable.

    A useful mental model: create a regional master file (core documents, SOPs, training), plus country modules (local submissions, contracts, import permits), plus site modules (delegation, logs, training, monitoring).

    FAQ

    When did Brazil’s latest clinical research regulations take effect?
    Brazil’s updated framework referenced by Anvisa includes Law 14.874/2024 (in force since 29 Aug 2024) and RDC 945/2024 plus IN 338/2024 (effective 2 Jan 2025).

    Do these changes apply to medical devices too?
    The Anvisa updates cited relate to clinical research for registration of medicines and biologics; device sponsors should still align operational quality systems and inspection readiness to ICH GCP expectations and local ethics requirements.

    How should startups prepare for inspection readiness?
    Build inspection-ready documentation from day one: role-based training, version-controlled essential documents, delegation logs, deviation management, and vendor oversight that can be demonstrated quickly.

    Need help designing a Latin America FIH plan? bioaccess® supports sponsors with regional feasibility, activation, and execution strategies built for speed and inspection readiness.